Por Renan Filho · 2026-10-07
**Lead**
The World Health Organization (WHO) has officially announced that weight loss injections, commonly referred to as 'jabs', are safe for use in obese teenagers, marking a significant shift in global paediatric health policy. The announcement, made earlier this week, is set to influence clinical practice across the United Kingdom, where rising rates of adolescent obesity have become a major public health concern. The WHO's endorsement, based on a comprehensive review of clinical evidence and ongoing international trials, is expected to open the door for wider prescription of GLP-1 receptor agonists to patients under the age of 18.
**Context**
Obesity among children and adolescents has reached crisis levels in the UK, with data from the National Health Service indicating that approximately one in five children leaves primary school classified as obese. For decades, the standard approach for teenage patients has been limited to lifestyle interventions, including dietary changes, increased physical activity and behavioural therapy. However, these measures, while valuable, have demonstrated inconsistent long-term success, particularly among adolescents with severe or complex obesity. The WHO's new guidance acknowledges that pharmacological intervention, when used alongside structured lifestyle programmes, offers a viable and effective alternative.
The endorsement comes after years of rigorous assessment of GLP-1 receptor agonists, a class of medications originally developed for Type 2 diabetes but increasingly recognised for their weight management properties. Drugs such as semaglutide and liraglutide have shown substantial efficacy in clinical trials involving adult populations, and more recent studies have investigated their safety and effectiveness in younger cohorts. The WHO's review highlighted that, when administered under appropriate medical supervision, these injections pose acceptable levels of risk for adolescents, with side effects being predominantly mild to moderate and transient in nature.
The decision was informed by long-term surveillance data from multiple countries, including the United States and several European nations, where off-label prescribing has been occurring for several years. The WHO also considered consultations with paediatric endocrinologists, sports medicine specialists and public health experts, all of whom contributed to a nuanced understanding of the unique physiological and psychological needs of teenage patients.
**Análise**
The announcement represents a fundamental recalibration of how medical institutions perceive obesity in adolescence. For years, there has been a reluctance to treat paediatric obesity with pharmaceutical interventions, largely due to fears about hormonal disruption, growth suppression and the psychological impact on young patients. The WHO's safety declaration counters these concerns with empirical evidence, suggesting that the benefits — including improved metabolic health, reduced cardiovascular risk and enhanced quality of life — outweigh the potential drawbacks when clinical governance is properly applied.
From a sporting and athletic perspective, the implications are profound. Schools, youth sports clubs and athletic academies across the United Kingdom have long struggled with how to support overweight and obese teenagers who participate in competitive activities. Obesity often creates a cycle of reduced physical capability, social withdrawal and declining participation in sports. With access to medically approved weight loss jabs, these young individuals may experience a more level playing field, potentially increasing their capacity for physical exercise and their willingness to engage in team sports. Sports physicians are now anticipating a scenario where weight management becomes an integrated component of athletic training and development programmes.
The announcement is also likely to influence NHS policy. Historically, the National Institute for Health and Care Excellence (NICE) has taken a guarded position on prescribing weight loss medication to under-18s, insisting on evidence of profound therapeutic benefit. With the WHO's explicit safety endorsement, NICE and local health authorities may revisit their current guidelines, accelerating the approval process and potentially expanding the availability of these treatments in primary care settings. This could alleviate pressure on specialist paediatric services, which currently face a significant backlog of obesity referrals.
Looking ahead, the WHO's position might catalyse further research into the long-term effects of these medications on adolescent development. While the safety profile is reassuring, longitudinal data spanning multiple decades is still incomplete. Researchers anticipate a wave of new trials focused specifically on teenage cohorts, examining both clinical outcomes and behavioural patterns. Additionally, the pronouncement could influence public perception, reducing stigma associated with medical weight loss interventions and encouraging earlier consultation among families who may have previously felt that no viable options existed.
**Fontes**
World Health Organization official statement on pharmacological management of obesity in adolescents; National Health Service England published obesity statistics; Royal College of Paediatrics and Child Health commentary on the WHO announcement; International Federation of Sports Medicine response to updated WHO guidelines.